MedTrace Logo

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®

NCT02823951 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 479

Last updated 2018-03-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the proportion of patients who demonstrate no medical need to discontinue therapy among DMT-naïve patients with relapsing forms of multiple sclerosis after 1 year of treatment with Rebif 44 mcg tiw or with Tecfidera 240 mg bid based on real-world data.

Conditions

  • Relapsing-remitting Multiple Sclerosis

Interventions

DRUG

Rebif

DRUG

Tecfidera

Sponsors & Collaborators

  • EMD Serono

    collaborator INDUSTRY

  • IMS HEALTH GmbH & Co. OHG

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2017-04-30
Completion
2018-02-28

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02823951 on ClinicalTrials.gov